ASP2138

DRUG3 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma

Phase 1

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

RecruitingNCT05365581

Astellas Pharma Global Development, Inc.Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

Start: 2022-06-07End: 2028-05-31Target: 398Updated: 2026-07-15

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

RecruitingNCT07024615

Astellas Pharma Global Development, Inc.Pancreatic Ductal Adenocarcinoma

Start: 2025-10-16End: 2028-01-31Target: 25Updated: 2026-07-15

Phase 3

A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Not yet recruitingNCT07673887

Astellas Pharma Global Development, Inc.Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma

Start: 2026-06-30End: 2031-02-28Target: 570Updated: 2026-06-29

Related Papers

Abstract 2962: ASP2138, a novel 2+1 format, claudin 18.2 x CD3 bispecific antibody, demonstrates selectivity and activity in preclinical cancer models

Cancer Research2023-04-048 citations